Uniphar (LON:UPR) Trading 1.5% Higher - Still a Buy?

Key Points

• Uniphar plc shares experienced a 1.5% increase, with trading prices reaching up to GBX 342.95 ($4.61) on Tuesday.
• Analysts largely support the stock, with a consensus rating of "Moderate Buy" and an average price target of GBX 427.50.
• The company has a substantial market capitalization of £882.55 million and operates in Ireland, the UK, and the Benelux region, serving over 200 pharmaceutical and medical technology manufacturers.

Uniphar plc (LON:UPR - Get Free Report) shares were up 1.5% during trading on Tuesday . The stock traded as high as GBX 342.95 ($4.61) and last traded at GBX 340 ($4.57). Approximately 54,122 shares were traded during trading, an increase of 9% from the average daily volume of 49,657 shares. The stock had previously closed at GBX 335 ($4.50).

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on UPR. Deutsche Bank Aktiengesellschaft restated a "hold" rating and issued a GBX 375 price target on shares of Uniphar in a research note on Wednesday, July 30th. Royal Bank Of Canada lifted their price objective on Uniphar from GBX 470 to GBX 480 and gave the stock an "outperform" rating in a report on Tuesday, September 9th. Two equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of GBX 427.50.

Uniphar Trading Up 1.5%

The company has a current ratio of 0.90, a quick ratio of 0.60 and a debt-to-equity ratio of 119.48. The stock has a market capitalization of £882.55 million, a PE ratio of 1,387.76 and a beta of 0.75. The stock has a 50 day moving average price of GBX 341.28 and a 200-day moving average price of GBX 298.69.

Uniphar Company Profile

Headquartered in Dublin, Ireland Uniphar plc is a diversified healthcare services business servicing the requirements of more than 200 multinational pharmaceutical and medical technology manufacturers across three divisions – Commercial & Clinical, Product Access and Supply Chain & Retail. With a workforce of more than 2,000, the Group is active in Ireland, the UK and the Benelux.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.